| Autor: |
Heron, JE, McManus, H, Vickers, T, Ryan, K, Wright, E, Carter, A, Stoove, Mark, Asselin, J, Grulich, A, Donovan, B, Guy, R, Varma, R, Chen, M, Ryder, N, Lewis, DA, Templeton, DJ, O’Connor, CC, Gracey, DM, Bastian, L, Bateson, D, Bowden, S, Boyd, M, Callander, D, Aung, HL, Cogle, A, Costello, J, Dimech, W, Dittmer, J, El-Hayek, C, Ellard, Jeannette, Fairley, C, Franklin, L, Hellard, M, Hocking, J, Kim, J, McGill, S, Nolan, D, Patel, P, Pendle, S, Polkinghorne, V, Nguyen, L, Nguyen, T, O’Connor, C, Reed, P, Roth, N, Selvey, C, Traeger, M, Walker, M, West, M |
| Rok vydání: |
2023 |
| Předmět: |
|
| DOI: |
10.26181/23119037 |
| Popis: |
Background: Tenofovir disoproxil fumarate (TDF) is associated with adverse renal outcomes when prescribed for HIV infection. There are few data concerning real-world renal outcomes amongst patients prescribed TDF for pre-exposure prophylaxis (PrEP). Methods and findings: Data were extracted from 52 sexual health clinics across Australia from 2009–2019. All patients prescribed TDF-containing antiretroviral therapy and PrEP were included. Rates of renal impairment (a fall in eGFR to |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
